Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Richard Dana Ono is Director at Lipocine. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 4, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
LipocineLPCN
Jun 3, 20261,764disclosed Jun 4
DetailsOfficial recordRichard Dana Ono bought shares on the open market in 2014 and 2023, and has not bought since 2023. Sales in 1 of the 13 years since 2014.
Richard Dana Ono reported 2 open-market purchases and 1 sale since 2014; purchases in 2 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $1.4K1×1 trade | — |
| 2017 | — | $3K1×1 trade |
| 2014 | $21K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Richard Dana Ono bought shares on the open market in 2014 and 2023, and has not bought since 2023. Sales in 1 of the 13 years since 2014.
In SEC filings since 2014: the latest open-market purchase is from 2023; the latest open-market sale is from 2017.
Lipocine (LPCN), from 2014 to 2023: 2 purchases and 1 sale.
Richard Dana Ono reported 2 open-market purchases and 1 sale here, 2014 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
